Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CMP-001 +/- Pembrolizumab in Advanced Melanoma
NCT02680184Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Apr 2016
- Primary completion
- Dec 2022
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Recombinant Protein Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of vidutolimod in melanoma (3 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Recommended Phase 2 Dose at 35 days and Treatment-Emergent Adverse Events up to 3.5 years. Started Apr 2016; status: completed.
02
Drugs
vidutolimod
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02680184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02680184.